Trial results

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

NCT06732245 on ClinicalTrials.gov · last registry update 2026-03-27

Registered but not yet open, with 224 participants planned. Due to report 15 August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change from baseline in body weight at 48 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Biomed Industries, Inc.

Sponsor type

Industry

Enrollment

224

Started

2026-08-15

Primary completion

2027-08-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline in body weight at 48 weeks

Conditions studied

Obesity and Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.